[Strategies to improve reperfusion with fibrinolytic therapy in ST-T elevation myocardial infarction].
The main targets in reperfusion strategies in early ST-T elevation acute myocardial infarction phase are to improve and sustain tisular perfusion. Due to its accessibility and effectiveness in reducing myocardial damage and mortality, fibrinolytic therapy has been considered as the standard treatment. The most serious fibrinolytic therapy dilemma is the high failure and reocclusion rate, secondary to resistance and rethrombosis phenomena. In ST-T elevation acute myocardial infarction, therapy fibrinolytic in combination with aspirin could be considered the most important treatment advance. In the injury vascular setting, thrombosis induced by thrombin and platelet aggregability is the responsible mechanism and could limit the effectiveness of fibrinolytic therapy. The current knowledge of coronary thrombus physiopathogenesis establishes the limitations of fibrinolytic therapy in the achievement of optimal lysis, and suggests the necessity of antithrombotic and reperfusion strategy combination. Through this synergism it is feasibly to modify thrombus components improving efficiently. The propose of this review is to deeply analyze the fibrinolytic therapy resistance mechanisms, the modern approach to improve tisular perfusion, including accelerated fibrinolytic regimens, facilitated fibrinolysis, low molecular weight heparin experience and the role of new antithrombotic drugs, that has proved effectiveness in non-ST elevation acute myocardial syndromes treatment.